Articles from Everest Medicines Limited

Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy

By Everest Medicines Limited · Via ACN Newswire · January 1, 2025

Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area

By Everest Medicines Limited · Via ACN Newswire · December 18, 2024

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

By Everest Medicines Limited · Via ACN Newswire · December 16, 2024

Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau

By Everest Medicines Limited · Via ACN Newswire · December 11, 2024

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

By Everest Medicines Limited · Via ACN Newswire · December 3, 2024

Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong

By Everest Medicines Limited · Via ACN Newswire · December 1, 2024